The Cancer Stem Cell Paradigm: Integrating Plasticity, Microenvironment, and Clinical Resistance

Abstract

Since their initial identification in leukemia, cancer stem cells (CSCs) have been recognized as critical targets for achieving durable oncological remissions. This type of self-renewing and differentiation potential cell is characterized by multidrug resistance, and radiation resistance, among others. In addition, they play a role in a variety of tumor malignancies, including recurrence, metastasis, heterogeneity, and multidrug resistance. In addition, the Stem cells divide into different forms, including (CSCs) several pluripotent transcription factors act as a role in stem cell differentiation, Many intracellular signaling pathways, including JAK-STAT (Janus kinase/signal transducers and Activators of transcription), A variety of extracellular factors, including vascular niches, Transforming Growth Factor (TGF)/SMAD, and PPAR (peroxisome proliferator-activated receptor), as well as PI3K/AKT/mTOR (phosphoinositide 3-kinase/AKT/mammalian target of rapamycin), are essential in regulating (CSCs) , including hypoxia, tumor-associated macrophages, cancer-associated fibroblasts, mesenchymal stem cells, extracellular matrix, and exosomes. Molecular therapeutics, vaccines, antibodies, and CAR-T cells have already been developed for the specific targeting of (CSCs). This review provides a comprehensive synthesis of current methodologies for CSC identification and characterization. It further delineates the molecular pathways and microenvironmental factors governing CSC dynamics and evaluates the clinical potential of emerging therapeutic strategies designed to eradicate these resilient cell populations.